Trials / Completed
CompletedNCT01890447
Assessing Contacts' Decision Making on Reducing the Risk of Pertussis Transmission to Newborns Through Immunisation
Assessing Contacts' Decision Making on Reducing the Risk of Pertussis Transmission to Newborns Through Immunisation, in Italy and Spain
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 676 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
This study aims to establish an effective method to inform parents or close relatives of newborns about the risk of pertussis transmission to newborns and the advantages offered by the cocooning strategy (vaccinating those who are in close contact with the newborn) by assessing the factors that affect the parents' decision-making to accept pertussis immunisation.
Detailed description
Two phases are foreseen in the study. The 'questionnaire design' phase will be conducted in order to finalise the electronic questionnaire. The enrollment phase will involve the administration of the final web-based questionnaires to the subjects included in the enrollment phase. The data generated in this study will be useful to inform parents of newborns about the advantages of vaccinating people who are in close contact with the newborn even before the baby is born in order to prevent the transmission of pertussis to the newborn. No vaccine will be administered during this study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Web-based survey questionnaire | Data collection will be done via web-based questionnaires generated by Sawtooth Software. Subjects will be asked for their ideal alternative (acceptance to immunisation) by selecting the factors that suit them the most. The subjects are then presented several sets of alternatives built around their ideal choice. |
Timeline
- Start date
- 2015-01-01
- Primary completion
- 2016-02-01
- Completion
- 2016-02-01
- First posted
- 2013-07-01
- Last updated
- 2017-01-18
Locations
9 sites across 2 countries: Italy, Spain
Source: ClinicalTrials.gov record NCT01890447. Inclusion in this directory is not an endorsement.